More funding for the brightest minds in blood cancer research is a top priority.
The next breakthroughs will come from innovative researchers and scientists working on better treatments for all types of blood cancer.
The Blood Cancer United Research Grant portfolio contains programs that span blood cancer research from the earliest phase of discovery science to translational research that goes from “bench to bedside,” to directly benefit people with blood cancer.
Providing support to today's promising, early-career scientists is fundamental to making sure that they will continue contributing to blood cancer research as tomorrow's leaders in the field.
Special, disease-focused Requests for Proposal (RFP) are announced regularly to accelerate research areas with high unmet needs.
Research grant programs
Blood Cancer United investigators are outstanding scientists at the forefront of research into hematologic malignancies at academic institutions throughout the world. Research grants are awarded for studies that range from basic blood cancer discovery science to research that has the potential to directly impact patients’ lives.
And we don't stop there. Blood Cancer United is also dedicated to funding blood cancer research to improve quality of life for patients and their families, with projects studying long-term and late effects of blood cancers.
Get details on academic grants that support and encourage basic, translational, and clinical blood cancer research.
Current funding opportunities
Explore available grant programs.
HCL2030
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) have joined forces to invest $5 to 7 million over approximately five (5) years in hairy cell leukemia (“HCL”) research, including the HCLF Patient Data Registry.
Open
Letters of Intent are due by: September 3, 2025
Apply to the HCL2030 Grant ProgramEquity in Access Research Grants
This grant supports the generation of evidence that will guide changes in healthcare policy and practice to ensure that all patients with and survivors of a blood cancer gain access to the cancer care and services they need throughout their lives.
Open
Letters of Intent are due by: September 11, 2025
Apply to the Equity in Access Research Grant ProgramTranslational Research Program (TRP)
This program funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application, otherwise known as bench to bedside.
Open
Letters of Intent are due by: October 16, 2025
Apply to the Translational Research ProgramCareer Development Program (CDP)
This program supports talented young early career physicians and scientists.
Open
Letters of Intent are due by: October 17, 2025
Apply to the Career Development ProgramThe Student Mentorship and Research Training (SMART) Program
This program provides medical students with an interest in blood cancer with an opportunity to engage in full time blood cancer laboratory research for one year.
Open
Letters of Intent are due by: October 17, 2025
Apply to the Student Mentorship and Research Training ProgramOther funding opportunities
These grant programs are currently closed.
Discovery Grant Program (DGP)
This program supports cutting edge, innovative, and discovery oriented research to understand blood cancer properties and vulnerabilities and aim toward advancing treatments for blood cancers.
Closed
Please check back for details.
Learn more about the Discovery Grant ProgramInfluential Medicine Providing Access to Clinical Trials (IMPACT)
Expanding access to high quality clinical trials to patients by bringing the trials to the patients at their local community oncology centers.
Closed
Please check back for details.
Learn more about IMPACT grantsMantle Cell Lymphoma Research Initiative II (MCL2)
Supports targeted research to better understand disease mechanisms, develop more efficacious treatments, and improve outcomes for MCL patients.
Closed
Please check back for details.
Learn more about the Mantle Cell Lymphoma Research Initiative IIResearch Accelerator for Follicular Lymphoma I (RAFL-I)
The Research Accelerator for Follicular Lymphoma I (RAFL-I) supports targeted research to better understand disease mechanisms, develop more efficacious treatments and improve the outcome for Follicular Lymphoma patients.
Closed
Please check back for details.
Learn more about the RAFL-I ProgramSpecialized Center of Research Program (SCOR)
This grant program brings together established investigators to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research.
Closed
Please check back for details.
Learn more about the Specialized Center of Research ProgramAcademic Clinical Trials Program (ACT)
This grant program enhances the development and implementation of academic investigator initiated clinical trials.
Closed
Please check back for details.
Learn about the Academic Clinical Trials Program
Specialized Center of Research Program (SCOR)
Bringing together established investigators to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research.
Therapy Acceleration Program® (TAP)
If you’re an academic investigator and know of a biotech company that could benefit from a collaboration with Blood Cancer United, learn more about becoming a TAP partner.
To move blood cancer research further and faster, Blood Cancer United forms partnerships with other organizations to fund promising blood cancer research together:
